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Abstract
Methylating agents are involved in carcinogenesis, and the DNA repair protein O6-methylguanine-
DNA methyltransferase (MGMT) removes methyl group from O6-methylguanine. Genetic variation
in DNA repair genes has been shown to contribute to susceptibility to squamous cell carcinoma of
the head and neck (SCCHN). We hypothesize that MGMT polymorphisms are associated with risk
of SCCHN. In a hospital-based case-control study of 721 patients with SCCHN and 1,234 cancer-
free controls frequency-matched by age, sex and ethnicity, we genotyped four MGMT
polymorphisms, two in exon 3, 16196C>T and 16286C>T and two in the promoter region, 45996G>T
and 46346C>A. We found that none of these polymorphisms alone had a significant effect on risk
of SCCHN. However, when these four polymorphisms were evaluated together by the number of
putative risk genotypes (i.e. 16195CC, 16286CC, 45996GT+TT, and 46346CA+AA), a statistically
significantly increased risk of SCCHN was associated with the combined genotypes with three to
four risk genotypes, compared with those with zero to two risk genotypes [adjusted odds ratio (OR)
= 1.27; 95% confidence interval (CI) = 1.05-1.53]. This increased risk was also more pronounced
among young subjects (OR = 1.81; 95% CI = 1.11-2.96), men (OR = 1.24; 95% CI = 1.00-1.55),
ever smokers (OR = 1.25; 95% = 1.01-1.56), ever drinkers (OR = 1.29; 95% CI = 1.04-1.60), patients
with oropharyngeal cancer (OR = 1.45; 95% CI = 1.12-1.87), and oropharyngeal cancer with regional
lymph node metastasis (OR = 1.52; 95% CI = 1.16-2.01). In conclusion, our results suggest that any
one of MGMT variants may not have a substantial effect on SCCHN risk, but a joint effect of several
MGMT variants may contribute to risk and progression of SCCHN, particularly for oropharyngeal
cancer, in non-Hispanic whites.
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1. Introduction
Squamous cell carcinomas of the head and neck (SCCHN), including those of the oral cavity,
pharynx, and larynx, are the sixth most frequently occurring cancers and the seventh leading
cause of cancer-related deaths worldwide [1]. In the United States, there were estimated to be
approximately 48,010 new cases of and 11,260 deaths from SCCHN in 2009 [2]. Although
tobacco use and alcohol consumption are the major risk factors for SCCHN [3], only a fraction
of exposed individuals develop this disease, suggesting that there exists individual
susceptibility to environmental exposure-related carcinogenesis.
The O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes
a methyl group from the O6-position in guanine and transfers it to its own cysteine residue at
codon 145 in the protein, inactivating the MGMT protein itself while repairing guanine [4].
Therefore, the MGMT protein plays an important role in removing major premutagenic lesions
induced by O6-methylating agents, preventing cytotoxicity and defending against both
endogenous and exogenous methylating agents [5]. The O6-methylguanine, a methylated DNA
adduct at the O6-position of guanine, may cause a G:C to A:T transition mutation during DNA
replication [6], sister chromatid exchanges, and chromosomal aberrations [7]. The detectable
levels of the MGMT protein vary in different tissues and types of the cells; in some tumor
tissues, MGMT expression appears to be upregulated, compared with the corresponding normal
tissue, with increasing tumor grading [8,9], but in others the expression level of the MGMT
protein tends to decrease in some tumor tissues [10], particularly in glioma, likely due to
promoter methylation [11], although deletion or point mutations and rearrangement of the
MGMT gene may not necessarily lead to the loss of MGMT activity [12]. Inactivation of the
MGMT gene by its promoter methylation is one of epigenetic regulation mechanisms in gene
expression, a common phenomenon observed in a variety of primary human tumors [10,13],
including SCCHN [11,14-19]. It has been reported that the MGMT knockout mice had a higher
incidence of nitrosamine-induced tumorigenesis [20]. Recently, loss of MGMT expression was
found to be common in oral leukoplakia and early oral cancer[21] and SCCHN [22] and was
associated with their progression[23]. Taken together, these data suggest that altered MGMT
expression may modulate susceptibility to SCCHN.
The MGMT gene is mapped on chromosome 10q26 and spans at least 15 kb [24,25]. To date,
a total of 1964 polymorphisms in human MGMT gene have been described
(http://www.ncbi.nlm.nih.gov/projects/SNP), but only two common, potentially functional
polymorphisms in exon 3 (rs1803965C>T Leu53Leu and rs12917C>T Leu84Phe) (GenBank
accession no: AL157832) [26-28] have been investigated for their association with cancer risk
[29,30], because they are commonly detected in all ethnic groups (Table 1). However, few
studies have investigated two new MGMT promoter polymorphisms: rs1711646C>A (formerly
named 135G>T) and rs1625649G>T (formerly named 485C>A) (GenBank accession no:
AL355531) (Table 1).
Most published studies have reported that both Leu53Leu and Leu84Phe polymorphisms are
not associated with cancer risk [27,31-34]. In a US study of lung cancer, we did not observe
any main effect of the selected four polymorphisms (135G>T, 485C>A, Leu84Phe and
IIe143Val, none of which was located on CpG methylation islands) on the risk [35]. In a
subsequent Chinese study of lung cancer with 39 MGMT variants as well as a subset of 10
haplotype-tagging SNPs (htSNP) and three pre- and interblock SNPs to capture variation across
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MGMT, we did not observe an association between cancer risk and any of these variants [36].
However, one study reported that both Leu84Phe and IIe143Val was associated with a
decreased risk of SCCHN in a pooled analysis of US populations [37], but in other studies
these two variants were not associated with oral cancer nor with secondary cancer.
Furthermore, we found a significant increased bladder cancer risk associated with the combined
genotypes of Leu53Leu and Leu84Phe polymorphisms [38].
To date, no reported study has investigated the association between the MGMT promoter
135G>T and 485C>A polymorphisms and risk of SCCHN. In the present study, we
hypothesized that these two MGMT promoter polymorphisms contribute to risk of SCCHN,
and we tested this hypothesis in our ongoing hospital-based case-control study of SCCHN.
Because we observed a combined effect of Leu53Leu and Leu84Phe on risk of bladder cancer
in a Chinese population [38], suffering from tobacco-induced cancer, we wished to replicate
this finding for SCCHN in a US population.
2. Materials and methods
2.1. Study subjects
The recruitment of study subjects has been previously described [39]. Briefly, the study
population included 721 patients with newly diagnosed SCCHN and 1 234 cancer-free control
subjects recruited between May 1995 and September 2003. Approximately 95% of the eligible
patients contacted chose to participate in this study. Only non-Hispanic white patients were
included in this analysis because genotype frequencies can vary between ethnic groups and
few patients of ethnic minority groups were recruited. Among the 721 SCCHN patients
included in the analysis, 222 (30.8%) had cancers of the oral cavity, 326 (45.2%) had cancers
of oropharynx, and 173 (24.09%) had cancers of larynx (including 37 of the hypopharynx).
Patients with second SCCHN primary tumors, primary tumors of the nasopharynx or sinonasal
tract, primary tumors outside the upper aerodigestive tract, cervical metastases of unknown
primary origin, or histopathologic diagnoses other than SCC were excluded. The regional
lymph node (N) involvement was defined as follows [40]: N0, no regional node metastasis;
N1, metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension; N2,
metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest
dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension;
or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension; N3,
metastasis in a lymph node more than 6 cm in greatest dimension.
Cancer-free control subjects were recruited from the biologically unrelated individuals who
were not seeking health care but accompaning the case patients to visit the clinics. We first
surveyed potential control subjects at the clinics using a short questionnaire to determine their
willingness to participate in research studies and to obtain demographic and risk factor
information. We frequency matched the controls to the cases by age (± 5 years) and sex. Among
the willing respondents we contacted for recruitment, the response rate was greater than 80%.
We interviewed each eligible subject to obtain data on tobacco smoke and alcohol use. After
signing informed consent forms, each subject donated 30 ml of blood, of which 1 ml used for
genomic DNA extraction with a DNA blood Mini Kit (Qiagen Inc., Valencia, CA) according
to the manufacturer's instructions. The research protocol was approved by the M. D. Anderson
institutional review board.
2.2. Genotyping
We determined the four MGMT polymorphisms by using the polymerase chain reaction-
restriction fragment length polymorphism method as previously described [38], which showed
that in these MGMT genotyping assays the genotyping gel pictures were very clear and easy
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to distinguish the genotypes in a double-blinded reading by two different lab personnel (the
first and second authors). The Hpy188I, EarI, ApeKI, and BanI restriction enzymes (New
England Biolabs, Beverly, MA) were used to distinguish the 16196C>T, 16286C>T,
45996G>T, and 46346C>A, respectively, which resulted in 121-bp and 58-bp fragments in the
presence of 16196C allele; 68-bp, 30-bp, and 4-bp fragments in the presence of 16286C allele;
168-bp, 44-bp, and 32-bp in the case of 45996G allele; and 139-bp and 73-bp in the case of
46346A allele. More than 10% of the samples were randomly selected for confirmation, and
the results were 100% concordant. The genotypes of 45996G>T, and 46346C>A were
confirmed by direct sequencing (Figure 1)
2.3. Statistical analysis
We used Chi-square test to evaluate the differences in the frequency distributions of selected
demographic variables, smoking status, alcohol use, and each allele and genotype of the four
MGMT polymorphisms between the cases and controls. Unconditional univariate and
multivariate logistic regression analyses were performed to obtain the crude and adjusted odds
ratios (ORs) and 95% confidence intervals (CIs). The multivariate adjustment included age,
sex, smoking status, and alcohol use. Considering the potential interaction of the MGMT
polymorphisms on SCCHN risk, the associations between the combined genotypes of the four
polymorphisms and SCCHN risk were evaluated. The 2LD software was used to calculate the
D’ value among the four polymorphisms [41,42]. The combined genotype data were further
stratified by subgroups of age, sex, smoking status, alcohol use, and the primary tumor sites,
e.g., oral cavity, the oropharynx, and larynx including hypopharynx. Two-sided tests of
statistical significance were conducted by using the SAS software (version 8.0; SAS Institute,
Inc., Cary, NC).
3. Results
The frequency distributions of selected characteristics of the cases and controls are presented
in Table 2. The cases and controls appeared to be well matched on age and sex: the mean age
was 57.0 years for cases (± 11.9 years; range, 18-90 years) and 57.1 years for controls (± 11.6
years; range, 20-87 years) (P = 0.287), and 74.9% and 25.1% of the cases and 74.1% and 25.9%
of the controls were men and women, respectively (P = 0.686). However, there were more
current smokers (34.8%) and current drinkers (51.2%) among the cases than among the controls
(25.4% and 43.7%, respectively), and these differences were statistically significant (P <
0.001). Therefore, these variables were further adjusted for in the multivariate logistic
regression analysis for any residual confounding effect.
3.1. Genotype distributions of the MGMT polymorphisms between the cases and controls
Genotype distributions and allele frequencies of the four MGMT polymorphisms in case
patients and control subjects and their associations with SCCHN risk are summarized in Table
3. We found no significant difference in the genotype distributions between the cases and
controls (P = 0.671 for 16195C>T, P = 0.395 for 16286C>T, P = 0.365 for 45996G>T, and
P= 0.183 for 46346C>A). The genotype frequencies of these four polymorphisms among the
controls were all in agreement with the Hardy-Weinberg equilibrium (chi-square test: P = 0.590
for 16195C>T, P = 0.377 for 16286C>T, P = 0.606 for 45996G>T, and P = 0.057 for
46346C>A).
As shown in Table 3, the frequencies of the 45996T and 46346A alleles (0.178 and 0.359,
respectively) among the cases were slightly higher than those among the controls (0.172 and
0.341, respectively), and in contrast, the frequencies of the 16195T and 16286T alleles (0.108
and 0.114, respectively) among the cases were slightly lower than those among the controls
(0.118 and 0.129, respectively), suggesting the 45996T, 46346A 16195C, and 16286C alleles
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may be the putative risk alleles to be considered in further combined analysis. Although none
of the variant genotypes was associated with significantly altered risk, both 45996T and
46346A alleles tended to be associated with non-significantly increased SCCHN risk (OR =
1.09 and 95% CI = 0.89-1.32 for 45996GT+TT and OR = 1.17 and 95% CI = 0.99-1.47 for
46346CA+AA), whereas both 16195T and 16286T alleles tended to be associated with non-
significantly reduced SCCHN risk (OR = 0.89 and 95% CI = 0.71-1.12 for 16195TT+TT and
OR = 0.87 and 95% CI = 0.70-1.08 for 16286CT+TT).
3.2. Distribution of the MGMT combined genotypes between the cases and controls
The LD analysis revealed that the alleles of two polymorphisms in exon 3 (i.e. 16195C>T,
rs1803965 and 16286C>T, rs12917) were in LD (D’ = 0.93 and R2 = 0.78), but the two
polymorphisms in the promoter region (i.e. 45996G>T, rs1711646 and 46346C>A, rs1625649)
were not (Figure 2A and 2B), among the controls. Because rs12917 (Leu84Phe) is a non-
synonymous SNP, we did a mini pool analysis of existing literature (Figure 3) and found that
the result of our overall risk estimate of the variant genotypes (84Phe, CT+TT) for SCCHN
(0.87, 0.70-1.08), the largest US study (the present study, Zhang 2009), was similar to that of
another US study [37] (0.78, 0.61-1.00) and a Tailand study [43] (1.00, 0.55-1.83) but
somewhat different from that of an European study [44] (1.60, 1.24-2.05). Overall, this single
variant was not associated with risk of SCCHN (1.02, 0.71-1.46) based on 1757 cases and 2901
controls in our pooled analysis of existing literature.
Considering possible combined effects from different variants or genotypes and potential
interactions of MGMT polymorphisms on risk of SCCHN, we combined these four MGMT
polymorphisms by the number of the putative risk genotypes (i.e. 16195CC, 16286CC,
45996GT+TT, and 46346CA+AA). As shown in Table 4, there were more individuals with
three risk genotypes and fewer individuals with two risk genotypes among the cases (49.0%
and 22.5%, respectively) than among the controls (43.9% and 27.3%, respectively), and these
differences were statistically significant (P = 0.014). When we dichotomized the combined
genotypes into two groups by the number of risk genotypes (i.e. 0-2 risk genotypes vs. 3-4 risk
genotypes), we found that the difference in the distribution of the combined genotypes between
the cases and controls was statistically significant (P = 0.012).
3.3. Association and stratification analysis between the MGMT combined genotypes and risk
of SCCHN
As shown in Table 5, we found that the combined genotype with 3-4 risk genotypes was
associated with a statistically significantly increased risk of SCCHN compared with those with
0-2 risk genotypes (OR = 1.27; 95% CI = 1.05-1.53). In the stratification analysis, we found
that the risk of SCCHN associated with 3-4 risk genotypes was decreased in a dose-response
manner as age increased; that is, the youngest subjects (≤ 45 years) with 3-4 risk genotypes
had the highest risk compared with those with 0-2 risk genotypes (OR = 1.81; 95% CI =
1.11-2.96 for aged ≤ 45 years, OR = 1.21; 95% CI = 0.91-1.61 for aged 46-60 years, and OR
= 1.16; 95% CI = 0.86-1.58 for aged > 60 years). This increased risk was also more pronounced
among men (OR = 1.24; 95% CI = 1.00-1.55), ever smokers (OR = 1.25; 95% CI = 1.01-1.56),
ever drinkers (OR = 1.29; 95% CI = 1.04-1.60), and patients with oropharyngeal cancer (OR
= 1.45; 95% CI = 1.12-1.87) than other subgroups in the same stratum (Table 5). However, no
statistical evidence was found for any interactions between the combined genotypes and these
variables (i.e. age, sex, smoking status, and alcohol use; data not shown).
3.4. Association between the MGMT combined genotypes and progression of SCCHN
Because the risk associated with the combined genotype with 3-4 risk genotypes was more
pronounced in oropharyngeal cancer, we then evaluated whether these polymorphisms had an
effect on tumor progression. As shown in Table 6, when we used the combined genotype with
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0-2 risk genotypes as the reference, we found that the combined genotype with 3-4 risk
genotypes was associated with a statistically significantly increased risk of oropharyngeal
cancer with regional lymph nodes metastasis (OR = 1.52; 95% CI = 1.16-2.01) but not
oropharyngeal cancer without regional lymph nodes metastasis (OR = 1.10; 95% CI =
0.61-1.97). In addition, we found also that the combined genotype with 3-4 risk genotypes was
associated with a statistically significantly increased risk of early-stage (T1-2) oropharyngeal
cancer (OR = 1.77; 95% CI = 1.28-2.44) but not late-stage (T3-4) oropharyngeal cancer (OR
= 1.09; 95% CI = 0.76-1.58). These were not observed for cancers of the oral cavity and larynx//
hypopharynx (data not shown).
Finally, because multiple tests had been performed, we calculated the false positive reporting
probability. As shown in Table 7, the positive findings for all subjects, ever smoker, and ever
drinking had a power greater than 80%, and they were unlikely chance findings.
4. Discussion
Our finding of no main effects of each MGMT variant on risk of SCCHN are consistent with
previously published studies [27,31-34], particularly for a large study of the upper
aerodigestive tract (UADT) [44], in which no main effects of Leu53Leu and Leu84Phe were
found on risk of SCCHN (n=438, including 117 oral cavity, 85 pharynx and 236 larynx),
compared with 529 controls. However, our finding of a non-significant protective effect from
16195T (53Leu) and 16286T (84Phe) alleles is also consistent with those reported in the pooled
analysis of SCCHN of 555 cases (430 whites) and 792 controls (695 whites) [37]. None of
these studies have investigated the effects of the promoter SNPs or combined variant genotypes
on SCCHN risk as in the present study that had the largest numbers of cases and controls
(Figure 2). Our results suggest that any one of the MGMT variants may not have a substantial
effect on SCCHN risk, but a joint effect of several MGMT variants may contribute to risk and
progression of SCCHN, particularly for oropharyngeal cancer, in non-Hispanic whites. Given
the role the MGMT gene may play in carcinogenesis, it is plausible that the MGMT
polymorphisms may modulate risk of SCCHN.
MGMT plays an important role in maintaining genomic integrity, and MGMT is a suicide repair
enzyme that is responsible for removing DNA damage induced by methylating agents [4], and
variation in its enzyme activity has been observed in SCCHN cell lines [45]. In the present
study, we found that those who carried the combined genotypes (i.e., 3 or 4 of the 16195CC,
16286CC, 45996GT+TT, and 46346CA+AA genotypes) with a greater number of risk
genotypes appeared to be at increased risk of SCCHN, although these polymorphisms
individually did not have a significant main effect. Specifically, the individuals with three to
four risk genotypes had a higher risk of SCCHN than those with zero to two risk genotypes,
and this increased risk was more pronounced among men, ever smokers, ever drinkers, and
patients with oropharyngeal cancer with regional lymph nodes metastasis.
Although how the two common MGMT polymorphisms in exon 3 affect the enzyme activity
remains to be investigated, some studies suggested that these two polymorphisms might affect
the protein function. It is reported that melanoma patients with the MGMT 16195T/16286T
variant alleles in the promoter had a high level of MGMT expression and that these two
polymorphisms may affect the methylation status of the MGMT gene and thus may have an
effect on MGMT protein expression and activity [32]. Recently, one study reported that the
level of MGMT expression was associated with the sensitivity of human oral cancer cell lines
to the alkylating agents, such as the anticancer drug, cis-diaminedichloroplatinum, suggesting
that abnormal MGMT expression may affect the DNA repair capacity and sensitivity in
response to chemotherapy of SCCHN [45]. Our finding of a positive association of select
MGMT polymorphisms with risk of SCCHN further supports the notion that some of these
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MGMT polymorphisms, or other untyped ones they may be in linkage with, may have an effect
on the MGMT activity. A possible explanation for the increased risk of SCCHN is that the
MGMT 84Phe mutant may have an effect on the MGMT Zn2+ binding (25) and thus on its
repair function and response to exposure to smoking (26). The other is that the MGMT-
dependent repair of the methylated DNA damage is weakened by the MGMT risk alleles or
those they represent as a result of affected MGMT protein expression and activity, particularly
for the MGMT polymorphisms in the promoter region. However, this hypothesis needs to be
confirmed by future functional studies.
The findings of no single polymorphism having a significant main effect on risk of SCCHN
are consistent with our previous study [38] and other published data [27,31,32,46]. Several
studies have reported that the variant genotype distributions of the 16286C>T between the
cases and controls were not significant different [31,33,34]. In the association studies, one
study reported that the 16286C>T polymorphism was not associated with increased risk of
lung cancer [46], but its small sample size (96 cases and 96 controls) did not have enough
statistical power to reveal any significant ORs. However, a recent study demonstrated that the
variant genotypes of the 16286C>T was associated with a significantly decreased risk of the
head and neck cancer in a population-based case-controls study [37]. The discrepancies in these
reported studies could be due to differences in study design and inclusion of different ethnic
groups (Table 1). For example, our results indicate that the genotype distributions of the
MGMT polymorphisms vary with ethnicity. The frequencies of the CC and CT genotypes of
the 16286C>T among our non-Hispanic whites were 75.6% and 23.0%, respectively, compared
with 84.8% and 13.7%, respectively, of our previous study of 204 southern Chinese controls
[38], 89.0% and 11.9%, respectively, of 100 southern Chinese population in the studies by Liu
et al. [33,34], and 83.6% and 16.2%, respectively, of 225 Japanese population in the study by
Otsuka et al. [26]. However, these ethnic variations in genotype distributions and their
influence on the risk of cancer need to be further investigated.
In this study, we found that the SCCHN risk associated with the combined genotype with 3-4
risk genotypes was more pronounced in oropharyngeal cancer, particularly for those with
regional lymph node metastasis, suggesting that the putative risk genotypes may be associated
with the progression of oropharyngeal cancer or perhaps with human papillomavirus-
associated oropharyngeal cancer (a disease almost always presenting with nodal metastases).
However, this finding from subgroup analysis could be due to chance. Larger studies are needed
to verify this finding. We found a higher risk in ever smokers and ever drinkers, suggesting
the risk-genotype carriers were at greater risk if they had continuous exposure. However, there
was no evidence of a gene-environment interaction, that is, tobacco smoke and alcohol use did
not modify the risk associated with the MGMT combined genotypes.
The strengths of our study include its relatively large sample size, use of combined risk
genotypes, and inclusion of the known polymorphisms within the exon and promoter region
of MGMT gene. Because our study was hospital-based, limitations inherent in the case-control
study design could introduce selection bias compared with population-based studies. However,
the genotype distributions in our study were similar to distributions reported in other studies.
For instance, the frequencies of the CC, CT, and TT genotypes of the 16286C>T among our
1 234 non-Hispanic white control subjects were 75.6%, 23.0%, and 1.4%, respectively,
compared with 70.4%, 26.9%, and 2.7%, respectively, of 665 white control subjects in the
study by Huang et al. [37]. Similarly, the genotype frequency of the 16195CT+TT among our
control subjects was 22.0% compared with 21.0% of 76 healthy Swedish population [32]. So
far, there are no reported frequencies of the 45996G>T and 46346C>A genotypes among
Caucasian populations to compare with. Because the genotype frequencies of the 16195C>T
and 16286C>T polymorphisms estimated from the hospital-based control subjects in our study
were very close to those of the population-based control subjects, any selection bias in genotype
Zhang et al. Page 7
DNA Repair (Amst). Author manuscript; available in PMC 2011 May 4.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
distribution is unlikely to be substantial. However, the positive findings in stratification
analysis may need further validation in larger studies.
5. Conclusion
We did not find any significantly increased risk of SCCHN associated with any of the
fourMGMT polymorphisms (i.e., 16196C>T, 16286C>T, 45996G>T, and 46346C>A), when
they were analyzed individually. This is consistent with published literature in which the SNPs
of MGMT either exhibited modest effects on the risk of cancer, or reportedly functional
MGMT SNPs did not have a major effect on protein function [29]. However, given only a
modest effect of each SNP individually, evaluating their combined effects may help us better
understand any role of MGMT SNPs may have in cancer etiology. Indeed, we found that the
combined genotypes of these four polymorphisms (i.e., 16195CC, 16286CC, 45996GT+TT,
and 46346CA+AA most risky genotypes, compared with the 16195TT+CT, 16286TT+CT,
45996GG, and 46346CC less risky genotypes) were associated with a statistically significantly
increased risk of SCCHN, and this increased risk was more pronounced among the young,
men, ever smokers, ever drinkers, and patients with oropharyngeal cancer. Although the
significance of these findings from subgroup analyses may be limited, the results do suggest
that the risk genotypes of the 16196C>T, 16286C>T, 45996G>T, and 46346C>A
polymorphisms may jointly contribute to risk and perhaps progression of SCCHN, particularly
for oropharyngeal cancer. Larger studies that include more detailed data on environmental
exposure (such as human papillomavirus) and more oropharyngeal cancers are required to
verify these findings.
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Fig 1.
Direct sequencing results for the MGMT -135G>T (GG, GT and TT) and -485C>A (CC, CA
and AA)
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Fig. 2.
Linkage disequilibrium (LD) display for the four MGMT variants. A, the D’ display and B, the
R2 display, both showed that rs1803965 (Leu53Leu53) and rs12917 (Leu84Phe) are in LD
with a D’ = 0.93 and R2 = 0.78
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Fig. 3.
Meta-analysis of associations between the functional MGMT Leu84Phe (rs12917) variant and
risk of SCCHN. The result of our overall risk estimate for SCCHN, the largest US study (Zhang
2009), was similar to that of another US study (Huang 2005) and a Tailand study (Kietthuthew
2006) but somewhat different from that of an European study (Hall 2007). Overall, this single
variant was not associated with risk of SCCHN.
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Table 6
Associations of the combined genotypes of MGMT polymorphisms with regional lymph nodes and tumor stage
of oropharyngeal cancera
Combined genotypes (No. of risk
genotypes)b
No regional lymph node metastasis (N0) Involvement of regional lymph nodes (N1-3)
Case/control (%) Adjusted OR (95% CI)c Case/control (%) Adjusted OR (95% CI)c
0-2 21/567 (43.7/46.0) 1.00 100/567 (36.0/46.0) 1.00
3-4 27/667 (56.3/54.0) 1.10 (0.61-1.97) 178/667 (64.0/54.0) 1.52 (1.16-1.89)
Combined genotypes (No. of risk
genotypes)b
T1-2 T3-4
Case/control (%) Adjusted OR (95% CI)c Case/control (%) Adjusted OR (95% CI)c
0-2 65/567 (33.0/46.0) 1.00 56/567 (43.4/46.0) 1.00
3-4 132/667 (67.0/54.0) 1.77 (1.28-2.44) 73/667 (56.6/54.0) 1.09 ( 0.76-1.58)
a
N, regional lymph node involvement. N0, no regional lymph nodes; N1, N2, and N3, increasing involvement of regional lymph nodes [40].
b
The number represents the numbers of risk genotypes; the risk genotypes used for the calculation were 16195CC, 16286CC, 45996GT+TT, and
46346CA+AA genotypes).
c
ORs were obtained from a multivariate logistic regression model with adjustment for age, sex, smoking status, and alcohol use.
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